In Europe epilepsy affects 6 million people of all ages and the lifetime risk for epilepsy is nearly 4%. Despite all advances, ~30% of patients are drug-refractory, with significant associated co-morbidities of depression, cognitive impairment and other neurodevelopmental and neuropsychiatric diseases. Most treatment decisions in epilepsy are largely based on “trial and error”. We do not yet have biomarkers for epilepsy that would provide us tools to individualize treatment choices. In the present study we will use modern machine learning algorithms to combine clinical, genetic, electrophysiological, imaging and circular biomarkers to predict response and better understand the interplay of epileptic activity and other pathophysiological processes of epilepsy in order to find biomarkers for epilepsy therapy. Apart from national single center studies, we participate in several large-scale international collaborations allowing increased throughput and cohort sizes.

2023

2027